Topical HPV Dosage Forms for Multilayer Cervical Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HPV infection and related conditions such as HPV-induced neoplasia, including cervical intraepithelial neoplasia, are inadequate, with existing drugs causing skin irritation, pain, and surgical interventions leading to scarring and increased risks of miscarriage, while there is a need for effective topical treatments that can penetrate multiple layers of cervical epithelium to treat transformed cells.
Innovation Solution
A specific salt form of Compound I, ethyl(((2-(2-amino-6-methoxy-9H-purin-9-yl)ethoxy)methyl)(benzyloxy)-phosphoryl)-L-alaninate, particularly its R,S monofumarate stereoisomer, is used in topical formulations like gels, creams, or tablets, which exhibit high tissue penetration and stability, effectively treating HPV-induced neoplasia by reaching and metabolizing to the active antiviral compound PMEG.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical interventions (LEEP, cryotherapy, laser therapy) are used to treat cervical intraepithelial neoplasia, then treatment effectiveness is improved, but scarring and increased risks of miscarriage occur
Solution Approach 1:
The patent replaces mechanical/surgical intervention methods (LEEP, cryotherapy, laser therapy) with a chemical/pharmaceutical treatment approach. The prodrug composition is applied topically to treat cervical intraepithelial neoplasia, eliminating the need for surgical procedures that cause scarring and miscarriage risks while maintaining treatment effectiveness through antiviral action.
Solution Approach 2:
The patent modifies the chemical structure and properties of the active compound by using a prodrug formulation with specific physical and chemical parameters (lipophilicity, molecular weight, stability) to enable effective penetration through cervical epithelium layers. This allows the treatment to reach transformed cells that are difficult to access with surgical methods.
2Adaptability or versatility
If existing drug therapies (salicylic acid, trichloroacetic acid, imiquimod, podofilox) are used, then HPV treatment options are provided, but skin irritation, pain, and chemical burning occur
Solution Approach 1:
The patent introduces a prodrug as an intermediary substance that converts into the active antiviral compound PMEG within the target tissue. This intermediary formulation reduces local irritation and pain during application while maintaining effective antiviral activity, as the prodrug itself is less irritating than the active compound would be at therapeutic concentrations.
Solution Approach 2:
The patent changes the chemical parameters of the treatment by using a prodrug formulation with modified pharmacological properties. The prodrug has different absorption, distribution, and irritation characteristics compared to the active compound, allowing for reduced local toxicity while maintaining efficacy through intracellular conversion to PMEG.
3Reliability
If treatments are applied to penetrate multiple layers of cervical epithelium, then transformed cells are reached, but formulation stability and penetration are difficult to achieve
Solution Approach 1:
The patent optimizes the physical and chemical parameters of the prodrug formulation, including lipophilicity, molecular weight, and structural stability, to simultaneously achieve effective penetration through multiple epithelial layers and maintain formulation stability. The prodrug is designed with specific pharmacokinetic properties that facilitate transcellular transport while remaining stable during storage and application.
Solution Approach 2:
The patent uses a composite formulation approach combining the prodrug with appropriate excipients and delivery system components to enhance both penetration capability and stability. The formulation integrates multiple functional elements that work together to protect the prodrug during storage while enabling effective delivery to deep tissue targets.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The R,S monofumarate stereoisomer of Compound I achieves significant tissue penetration and stability, reaching concentrations of 40-85 ng/mL in vaginal tissue, surpassing previous formulations, and is effective in treating HPV-induced neoplasia without systemic toxicity, thereby preventing the progression to cancer.
Implementation Method 1
The R,S monofumarate stereoisomer of Compound I achieves significant tissue penetration and stability, reaching concentrations of 40-85 ng/mL in vaginal tissue
Implementation Method 2
Compound I is an acyclic nucleotide phosphonate that metabolizes to a known potent antiviral compound (PMEG; ((9-[2-phosphonomethyoxy)ethyl)guanine))
Data Source
AI summary
A pharmaceutically acceptable salt of an acyclic nucleotide phosphoramidate to treat HPV and related conditions including neoplasia, as well as pharmaceutical compositions, morphic forms and dosage forms thereof.